ClinicalTrials.gg
RecruitingNCT06592859NMNAGINGUpdated May 8, 2026

Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People

An interventional study of NMN and placebo in Aging and NMN, sponsored by People's Hospital of Quzhou. Recruiting at 1 site in China. Open to participants aged 39 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by People's Hospital of Quzhou · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Registered 11 months after the study started (first participant enrolled Aug 2023, registered Jul 2024).
  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
39 Years to 70 Years
Sex
All
01

Study summary

This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging and improve the quality of life in the elderly population. The main outcomes of this study are to characterize the patterns of NMN efficacy across different populations and to identify sensitive biomarkers that reflect responsiveness to the intervention.

02

Conditions studied

  • Aging
  • NMN

Keywords

  • Aging
  • NMN
03

In context

Lead sponsor

People's Hospital of Quzhou is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
39 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Local residents of Quzhou or living in Quzhou for over ten years.
  2. age 40-50 and 60-70 years old, no major bad habits.
  3. Gender unlimited.
  4. in good health and has not undergone major surgery within half a year.
  5. Be able to communicate well with researchers and cooperate with the work during the study.
  6. Written can be signed voluntarily.

Exclusion criteria

Exclusion criteria:

  1. Alcoholism, heavy smoking (more than 5 packs/day, 20 cigarettes per pack), drug abuse or substance abuse.
  2. Participants are conducting other clinical trials or using any research drugs or equipment for treatment within 30 days before enrollment (including but not limited to aspirin, metformin, resveratrol, vitamin C, etc.).
  3. Obesity (bmi more than 30).
  4. Pregnant/lactating women.
  5. Disease history:

    A) under 60 years old:

    1. any cancer (erythrocytosis, except basal cell or squamous cell skin cancer).
    2. coronary artery disease/myocardial infarction/ congestive heart failure.
    3. stroke/.
    4. deep vein thrombosis/pulmonary embolism.
    5. serum creatinine > 1.5 mg/dl (male).
    6. poor control of hypertension (although treated, there is still significant hypertension (systolic blood pressure > 160 mmHg, or diastolic blood pressure >100 mmHg)).
    7. history of active liver disease or metabolic acidosis.
    8. chronic kidney disease/hemodialysis treatment, history of severe kidney damage and/or EGFR ≤ 45ml/min/1.73m2.
    9. severe autoimmunity/inflammation, such as rheumatoid arthritis, lupus, Crohn\'s disease, etc.
    10. nervous system diseases such as dementia, such as Alzheimer/Parkinson\'s disease.
    11. diabetes mellitus ( > 6.5% or fasting blood glucose > 126 mg/dL or taking diabetes drugs or insulin treatment).
    12. recent (within 3 months) cardiovascular events (myocardial infarction, coronary intervention, coronary artery bypass grafting).
    13. infectious diseases such as , hepatitis, tuberculosis, etc.
    14. hand or lower limb disability affects normal function and life.

    B) older than 60 years:

    1. any cancer (erythrocytosis, except basal cell or squamous cell skin cancer).
    2. history of active liver disease or metabolic acidosis.
    3. chronic kidney disease/hemodialysis treatment, history of severe kidney damage and/or EGFR ≤ 45ml/min/1.73m2.
    4. severe autoimmunity/inflammation, such as lupus, Crohn\'s disease, etc.
    5. nervous system diseases such as dementia, such as Alzheimer/Parkinson\'s disease.
    6. recent (within 3 months) cardiovascular events (myocardial infarction, coronary intervention, coronary artery bypass grafting).
    7. infectious diseases such as HIV, hepatitis, tuberculosis, etc.
    8. hand or lower limb disability affects normal function and life.
  6. Currently taking the following drugs regularly:

    A) chemotherapy drugs (such as tamoxifen, adriamycin, mitoxantrone, bleomycin). B) antiplatelet drugs (e.g., clopidogrel/Plavix, dipyridamole/anglionide, ticlopidine/ticlopidine, except aspirin).

    C) cholinesterase inhibitors for Alzheimer\'s disease (donepezil/alicept).

  7. The researchers believe that the physical factors of the participants may have an adverse impact on the research process or results.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    NMN treated (middle-aged female)

    NMN Arm participants (middle-aged female) took one capsule (containing 350mg NMN) with breakfast daily for one year.

    Dietary Supplement: NMN

  • Placebo comparator
    Placebo (middle-aged male)

    Placebo arm participants (middle-aged male) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.

    Dietary Supplement: placebo

  • Experimental
    NMN treated (middle-aged male)

    NMN Arm participants (middle-aged male) took one capsule (containing 350mg NMN) with breakfast daily for one year.

    Dietary Supplement: NMN

  • Experimental
    NMN treated (old female)

    NMN Arm participants (old female) took one capsule (containing 350mg NMN) with breakfast daily for one year.

    Dietary Supplement: NMN

  • Experimental
    NMN treated (old male)

    NMN Arm participants (old male) took one capsule (containing 350mg NMN) with breakfast daily for one year.

    Dietary Supplement: NMN

  • Placebo comparator
    Placebo (middle-aged female)

    Placebo arm participants (middle-aged female) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.

    Dietary Supplement: placebo

  • Placebo comparator
    Placebo (old male)

    Placebo arm participants (old male) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.

    Dietary Supplement: placebo

  • Placebo comparator
    Placebo (old female)

    Placebo arm participants (old female) took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.

    Dietary Supplement: placebo

Interventions

  • Dietary supplementNicotinamide MononucleotideStudies of Nicotinamide MononucleotideNicotinamide Mononucleotide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    NMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year.

  • Dietary supplementplacebo

    Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.

06

What researchers measure

Primary outcomes

  1. Comprehensive evaluation of NMN in reducing biological age

    Change in biological age from baseline to 12 months, quantified using predefined multi-layer aging clock(s). Biological age will be assessed using the following measures: 1. Transcriptomic age (years) 2. DNA methylation age (years) 3. Proteomic age (years) 4. Metabolomic age (years) 5. Phenotypic age (years) The primary endpoint will be defined as: Change from baseline to 12 months in a prespecified composite biological age score, derived from the above aging clocks using a predefined integration method (e.g., standardized z-score aggregation or principal component-based integration). A reduction in biological age is defined as a decrease in the composite biological age score.

    Time frame: Baseline, 6 months and 12 months

Secondary outcomes

  1. Composite through clinical physical examination data, behavioral indicators and multilevel omics data, to discover new sensitive biomarkers for evaluating aging.

    NMN intervention-associated changes will be evaluated across predefined domains: 1. Clinical examination parameters, such as: 1. Bone mineral density (g/cm²) 2. Pulmonary function, including FEV1 (L), FVC (L), and FEV1/FVC (%) Each parameter will be analyzed individually. 2. Functional performance measures, such as: 1. Grip strength (kg) 2. Purdue Pegboard Test completion time (s) Improvement is defined as an increase in grip strength and a decrease in completion time. 3. Inflammatory and clinical biomarkers, such as: Circulating inflammatory markers (e.g., IL-6 \[pg/mL\], CRP \[mg/L\]) Improvement is defined as a reduction in these markers. 4. Multi-omics-derived aging biomarkers, such as: Gene expression, proteomic, and metabolomic profiles related to metabolism, immunity, and aging. These measures will be summarized using: Predefined composite aging scoresm, biological ages, or principal component-based or pathway-level summaries, depending on the analysis framework.

    Time frame: Baseline, 6 months and 12 months

07

Study locations

1 of 1 sites recruiting
  • People's Hospital of Quzhou
    Quzhou, Zhejiang 324000, China
    Recruiting
    • Beier Jiang · Contactbeierjiang@wmu.edu.cn · +86-18367091390
    • Feng Zhang, Professor · Principal investigator
    • Guanghui Liu, Professor · Sub investigator
    • Weiqi Zhang, Professor · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for May 2026, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Sep 19, 2024
StartActual
Aug 23, 2023
Primary completionEst.
May 24, 2026
CompletionEst.
Dec 31, 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06592859
Lead sponsor
People's Hospital of Quzhou
Collaborators
Beijing Institute of Genomics, Chinese Academy of Sciences, Institute of Zoology, Chinese Academy of Sciences
Responsible party
Feng Zhang (researcher, People's Hospital of Quzhou) — Principal investigator
First posted
Sep 19, 2024
Start date
Aug 23, 2023
Primary completion
May 24, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 8, 2026

Study contacts

Feng Zhang
Contact
felix.f.zhang@outlook.com
+86-15657053100

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nicotinamide Mononucleotide

Start the discussion